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Abstract
The continued spread of highly pathogenic H5N1 influenza viruses among poultry and wild birds, together with the
emergence of drug-resistant variants and the possibility of human-to-human transmission, has spurred attempts to develop
an effective vaccine. Inactivated subvirion or whole-virion H5N1 vaccines have shown promising immunogenicity in clinical
trials, but their ability to elicit protective immunity in unprimed human populations remains unknown. A cold-adapted, live
attenuated vaccine with the hemagglutinin (HA) and neuraminidase (NA) genes of an H5N1 virus A/VN/1203/2004 (clade 1)
was protective against the pulmonary replication of homologous and heterologous wild-type H5N1 viruses in mice and
ferrets. In this study, we used reverse genetics to produce a cold-adapted, live attenuated H5N1 vaccine (AH/AAca) that
contains HA and NA genes from a recent H5N1 isolate, A/Anhui/2/05 virus (AH/05) (clade 2.3), and the backbone of the cold-
adapted influenza H2N2 A/AnnArbor/6/60 virus (AAca). AH/AAca was attenuated in chickens, mice, and monkeys, and it
induced robust neutralizing antibody responses as well as HA-specific CD4+ T cell immune responses in rhesus macaques
immunized twice intranasally. Importantly, the vaccinated macaques were fully protected from challenge with either the
homologous AH/05 virus or a heterologous H5N1 virus, A/bar-headed goose/Qinghai/3/05 (BHG/05; clade 2.2). These results
demonstrate for the first time that a cold-adapted H5N1 vaccine can elicit protective immunity against highly pathogenic
H5N1 virus infection in a nonhuman primate model and provide a compelling argument for further testing of double
immunization with live attenuated H5N1 vaccines in human trials.
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Introduction
In 1996, a highly pathogenic H5N1 avian influenza virus was
detected in geese in China [1]. A year later, a reassortant H5N1
virus caused disease outbreaks in poultry in Hong Kong [2] and
was transmitted to humans, infecting 18 people, six of whom died
[3,4]. Beginning in late 2003, outbreaks of H5N1 influenza A virus
infection appeared among poultry, and wild birds in numerous
countries in Asia and subsequently were reported in Europe and
Africa (Office International des Epizooties [OIE]; http://www.oie.
int). Despite substantial efforts to control the infection in poultry,
H5N1 viruses have continued to evolve and spread, producing
human infections in 14 countries, with 236 of the 372 confirmed
cases proving fatal (World Health Organization [WHO]; http://
www.who.int). The emergence of H5N1 viruses resistant to
adamantanes and oseltamivir [5,6,7] has raised serious concerns
over the ability of current antiviral agents to prevent global
influenza outbreaks. Thus, the development of an effective vaccine
has assumed the highest priority in preparedness for an H5N1
influenza pandemic.
H5N1 inactivated vaccines can induce functional and cross-
reactive antibodies that protect ferrets or nonhuman primates
from H5N1 infection [8], and have been shown to be safe and
tolerable in human trials [9,10,11]. With the addition of adjuvants,
such vaccines induce antibody titers that are known to provide
protection against seasonal influenza in humans [11], however, the
antibody level considered to be protective was based on findings in
humans who had likely been exposed to the seasonal human virus
and thus were ‘‘preimmunized’’. Because the vast majority of
humans have not been exposed to highly pathogenic H5N1
viruses, it is still unknown whether the level of antibody known to
be protective against seasonal human influenza virus infection
would also be effective against H5N1 viruses. Additionally, while
humoral immunity is effectively induced by the inactivated
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raised concern because of indications that the cellular immune
response may play a significant role in protection against H5N1
infection [12].
The cold-adapted (ca) influenza virus A/Ann Arbor/6/60 (AA)
(H2N2) has been developed as a live attenuated vaccine seed virus
that exhibits cold-adaptation, temperature-sensitive (ts), and atten-
uation (att) phenotypes which are specified by mutations in the
internal genes. Reassortant H1N1 and H3N2 human influenza A
viruses with the six internal gene segments of the AAca virus have
been repeatedly demonstrated to bear these phenotypes and
extensive evaluation in humans has proven them to be attenuated
and safe as live virus vaccines (reviewed in [13–15]). In previous
studies, live attenuated H5N1 vaccines generated by reverse genetics
and comprising internal genes of the AAca virus and the HAand NA
genes derived fromearlierH5N1influenzaviruses wereproved tobe
safe in mice and ferrets, and to protect these animals from death
against different H5N1 viruses challenges [16,17]. In this study, we
produced three live attenuated, ca H5N1 viruses, using reverse
genetics,thatcontaintheHAand NAgenesofH5N1virusesisolated
at different times and from different species in China. After in vitro
and in vivo analyses, one of the cold-adapted virus that contains the
HA and NA genes from a recent H5N1 virus, A/Anhui/2/2005
(AH/05) (clade 2.3), was selected for immunogenicity and efficacy
testing in mice and nonhuman primates.
Results
Generation and characterization of H5N1 cold-adapted
reassortant viruses
We constructed three H5N1 reassortant virus by reverse
genetics [18,19,20], using the published sequences of the low
pathogenic A/Ann Arbor/6/60 ca virus (AAca) [21] to generate
all of the genes encoding the internal proteins. The HA and NA
genes were from the highly pathogenic H5N1 influenza viruses,
including A/goose/Guangdong/1/1996 (GS/GD/96) (clade 0),
A/chicken/Shanxi/2/2006(CK/SX/06), a virus isolated from
chickens in northern Chine in 2006, and A/Anhui/2/2005 (AH/
05) (clade 2.3), which was isolated from a human in China (WHO;
http://www.who.int). The multiple basic amino acids at the HA
cleavage site, a major virulence motif for H5N1 influenza viruses,
were replaced with those found at the HA cleavage site of a
nonpathogenic avian influenza virus, as previously described
[16,22]. The cold-adapted (ca) and temperature-sensitive (ts)
phenotypes of the resultant viruses GSGD/AAca, CKSX/AAca,
and AH/AAca, attributable to the internal genes of AAca, were
also confirmed as described previously (data not shown). The ca
reassortant viruses did not cause disease or death in chickens upon
intranasal or intravenous administration, while all of the three
wild-type H5N1 viruses are lethal to chickens (Table 1).
Replication and immunogenicity of the reassortant
viruses in mice
We evaluated the replication of GSGD/AAca, CKSX/AAca,
and AH/AAca, in mammals, using the BALB/c mouse. Groups of
6-week-old female BALB/c mice were inoculated intranasally with
10
6 EID50 (dose required to infect 50% of eggs) of the reassortant
Table 1. Attenuation phenotype of the recombinant AH/AAca virus in chickens.
Virus Observations after intranasal inoculation
a Observations after intravenous inoculation
b
Virus shedding on day 3
(log10 EID50)
Virus shedding on day 5
(log10 EID50) No.SC./total
No.sick
deaths/total
c No.sick/deaths/total No.SC/total IVPI
Oropharyngeal Cloacal Oropharyngeal Cloacal
GSGD/AAca ,, ,, 0/6 0/0/6 0/0/10 2/10 0
GS/GD/96 3.260.3 2.460.8 2.460.3 2.860.6 NA 0/6/6 1/9/10 1/1 2.1
CKSX/AAca ,, ,, 0/6 0/0/6 0/0/10 3/10 0
CK/SX/06 3.260.6 2.160.4 2.5 3.0 NA 0/6/6 0/10/10 NA 2.8
AH/AAca ,, ,, 0/6 0/0/6 0/0/10 2/10 0
AH/05 2.460.6 1.760.6 1.460.1 1.860.1 NA 0/6/6 0/10/10 NA 2.5
aSix-week-old specific-pathogen free chickens were inoculated i.n. with 10
6 EID50 of virus in a 0.1-ml volume. Swabs were collected from the birds on day 3 and day 5
postinoculation and titrated in eggs. ,, virus not detected. data are means6standard deviations. No. sick/deaths/total; numbers of chickens that were sick and died, as
well as the total number of chickens during the observation period. Birds that showed disease signs, such as depression and ruffled feathers, but recovered at the end
of the observation were counted as sick animals. SC/total, number of chickens that seroconverted out of the total number of chickens at the end of the 2-week
observation period. NA, all birds died by the end of the observation period and thus could not be studied for sera conversion.
bSix-week-old white Leghorn chickens housed in high-efficiency particulate air-filtered isolators were inoculated i.v. with 0.2 ml of a 1:10 dilution of bacterium-free
allantoic fluid containing virus for intravenous pathogenicity index (IVPI) testing, based on recommendations of the Office International Des Epizooties.
cOnly animals that showed disease signs but recovered by the end of the observation period were identified as sick birds.
doi:10.1371/journal.ppat.1000409.t001
Author Summary
H5N1 influenza viruses have caused human infections with
more than 60% fatality in 14 countries and may yet be the
source of the next pandemic. Therefore, the development
of effective vaccines against these viruses is the highest
priority for H5N1 pandemic preparedness. A high dosage
or adjuvants improve the immunogenicity of H5N1
inactivated vaccines; however, limited production capacity
for conventional inactivated influenza virus vaccines could
severely hinder the ability to control the spread of H5N1
influenza through vaccination. Here, we generated and
tested the efficacy of a cold-adapted, live attenuated H5N1
vaccine in mice and nonhuman primates. We found that
the vaccine provided complete protection in these animals
against homologous and heterologous H5N1 virus chal-
lenge. Since live vaccines require less processing than
inactivated vaccines and do not require adjuvants, our
study represents a major advance in vaccine development
for H5N1 pandemic influenza.
Live Vaccine for H5N1 Influenza
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were killed on day 3 postinoculation (p.i.) and their organs were
collected for virus titration. As previously reported [1], the
replication of the wild-type GS/GD/96 virus was not detected
in any organs on day 3 p.i.; however, the ca virus GSGD/AAca
was detected in the nasal turbinate of the inoculated mice at this
timepoint (Table 2). The wild-type CK/SX/06 virus replicated in
the nasal turbinate and lung, while the replication of the
reassortant ca virus CKSX/AAca was not detected in any organs
(Table 2). The wild-type AH/05 replicated systemically with high
virus titers in all of the organs examined. The replication of AH/
AAca, by contrast, was restricted to the respiratory system. Even in
lung, the AH/AAca titer was significantly lower than that for AH/
05 (Table 2). The reassortant viruses, as well as the wild-type GS/
GD/96 and CK/SX/06 viruses did not kill any mice at the
highest inoculation dose, whereas the AH/05 virus killed mice at a
very low dosage (MLD50=1.5 log10EID50) (Table 2).
We then evaluated the immunogenicity of the three reassortant
ca H5N1 viruses in mice. Four weeks after the first intranasal
immunization of GSGD/AAca, hemagglutinin inhibition (HI)
antibody against the homologous virus GS/GD/96 was not
detected, but the neutralization (NT) antibody titers was 320. After
the second vaccination, the HI and NT antibodies increased
sharply to titers of 80 and 1067, respectively (Table 3). HI and NT
antibodies in the CKSX/AAca-inoculated mice were not detected
even after the second vaccination (Table 3). However, both HA
and NT antibodies were detected in mice after one vaccination of
the AH/AAca virus, and the mean titers increased sharply after the
second vaccination (Table 3). These results indicate that the AH/
AAca virus induced a better immune response than the other two
ca reassortant viruses. Therefore, we selected the AH/AAca virus
for further vaccine efficacy investigations in mice and monkeys.
Protective efficacy of the AH/AAca vaccine in mice
We first evaluated the protective efficacy of the AH/AAca
vaccine in mice. By 4 weeks after the first intranasal immunization
of 10
6 EID50 of AH/AAca, the mean6s.d. titers of HI and NT
antibodies against the homologous AH/05 virus had increased
significantly over the pretest values (P,0.01) (Figure 1A and 1B).
They also rose sharply after the second vaccination (P,0.01 [HI],
P,0.05 [NT]) (Figure 1A and 1B). Antibodies to the heterologous
A/bar-headed goose/Qinghai/3/05 (BHG/05) (clade 2.2) virus
were either undetectable (HI) or increased (NT) after the first
vaccination, rising to 80623 (HI, P,0.01) and 5336184 (NT,
P,0.05) after the second immunization (Figure 1A and 1B).
Four weeks after vaccination, we challenged the mice
intranasally with a lethal dose (10
2 LD50) of two different H5N1
viruses, AH/05 and BHG/05, whose genetic and antigenic
properties are different from those of the AH/05 virus. Three
mice were killed on day 3 postchallenge, and their organs were
collected for virus titration; the remaining seven mice in each
group were observed for 2 weeks. As shown in Figure 1C–1E, mice
were completely protected from homologous AH/05 virus
challenge in both the single- and two-vaccination groups. Virus
was not detected in any of the organs tested, and the mice
remained healthy over the 2 weeks of observation (no weight loss).
By contrast, the virus replicated systemically and was detected in
all of the test organs in unvaccinated mice, with death occurring
between 6 and 10 days postchallenge. In mice challenged with
BHG/05, virus was detected at low titers (,2 log10 EID50 g
21)i n
the nasal turbinates of animals that had received a single dose of
vaccine, but was undetectable in the organs from mice that were
vaccinated twice (Figure 1F). All of the vaccinated mice remained
healthy during the 2-week observation period, whereas the virus
replicated systemically and killed all of the mice within 10 days
postchallenge in the unvaccinated group (Figure 1G and 1H).
Humoral and cellular immune responses to the AH/AAca
vaccine in rhesus macaque
To assess the immunogenicity of the AH/AAca reassortant virus
in a rhesus macaque (Macaca mulatta) model, we inoculated 2- to 3-
year-old female animals (n=8, Vaccinated 1–8, V1–V8) intrana-
Table 2. Replication of the H5N1 ca reassortants and the wild-type H5N1 viruses in mice.
Virus Mean virus titer (log10 EID50/ml6SD) on day 3 post inoculation in:
a
MLD50 (log10EID50)
Turbinate Lung Spleen Kidney Brain
GSGD/AAca 3.160.6 ,, , , . 7.5
GS/GD/96 , , ,,,. 8.0
CKSX/AAca , , ,,,. 7.8
CK/SX/06 1.860.6 4.460.8 ,,,. 6.5
AH/AAca 3.860.1 3.760.5
b ,,,. 7.2
AH/05 4.760.9 6.561.2 2.760.8 2.060.5 2.661.0 1.5
aSix-week-old BALB/c mice (3 per group), inoculated intranasally with 10
6 EID50 of the indicated virus in a 50-ml volume, were killed on day 3 postinoculation and their
organs were collected for virus titration in eggs. ,, no virus was isolated from that sample.
bP value was,0.01 compared with the titers in the corresponding organs of the AH/05-inoculated mice.
doi:10.1371/journal.ppat.1000409.t002
Table 3. Antibody response induced by the H5N1 ca
reassortant viruses in mice.
Virus Mean antibody titers in mice
Pretest Dose 1 Dose 2
HI NT HI NT HI NT
GSGD/AAca ,5 ,10 ,5 320 80 1067
CKSX/AAca ,5 ,10 ,5 ,10 ,5 ,10
AH/AAca ,5 ,10 26.7 533 480 1573
Group of five six-week-old BALB/c mice were inoculated with two dose, in a 4
week interval, of 10
6 EID50 of the indicated H5N1 ca reassortant virus. Four
weeks after dose 1 or dose 2, sera were collected for determining the HI and NT
antibodies using the homologous wild type H5N1virus.
doi:10.1371/journal.ppat.1000409.t003
Live Vaccine for H5N1 Influenza
PLoS Pathogens | www.plospathogens.org 3 May 2009 | Volume 5 | Issue 5 | e1000409sally with 10
7 EID50 of the AH/AAca virus in a 1-ml volume,
twice, at a 4-week interval. A control group (n=8, Control 1–8,
C1–C8) received the same volume of phosphate-buffered saline
(PBS). Serum was collected from each animal at 4 weeks after the
first vaccination (week postvaccination dose, wpd1) and at 2 weeks
after the second vaccination (wpd2). Peripheral blood mononu-
clear cells (PBMCs) of the monkeys were isolated at different times
for detection of a T-cell immune response using an H5-HA specific
IFN-c ELISPOT assay. Intranasal inoculation of the AH/AAca
virus was not associated with any adverse events (not shown).
As shown in Figure 2A, each of the vaccinated macaques had a
detectable antibody response by ELISA (enzyme-linked immuno-
sorbent assay) at 2 weeks after the first inoculation, with the titer
ranging from 120–780 (median, 760), and the titers increased
sharply at 4 weeks after the first inoculation, with titers ranging
from 1520 to 12780 (median, 7640). HI and NT antibodies were
not detectable from the animals at 2 weeks after the first
inoculation (data not shown). Five of these animals developed
HI antibodies to the AH/05 virus (titers, range of 10–80, median,
40), and all had NT antibodies to this virus (range of titers, 40–
640, median 240) (Figure 2B and 2D) at 4 weeks after the first
inoculation. Antibody levels in the vaccinated animals increased
significantly after the second vaccination (Figure 2). Eight animals
had detectable HI antibody to AH/05 (range of titers, 40–640;
median, 160) at 2 weeks after the second vaccination, while NT
and ELISA antibody titers reached 320–2560 and 25,118–
199,526, respectively, at this interval (Figure 2A, 2B, and 2D).
Overall, the HI and NT antibody titers against the heterologous
virus BHG/05 (Figure 2C and 2E) were 2- to 4-fold lower than
those against the AH/05 virus. T cell responses to the HA protein
were not detected at 4 weeks after the first immunization.
However, the HA-specific T cell responses could be detected at 2
weeks after the second immunization in all vaccinated macaques
(Figure 3). Interestingly, 11 of the 13 T cell HA-specific peptides
identified in samples from eight macaques represented CD4+ T
cells (Table 4), suggesting this T cell subset may have played a role
in the generation of antibodies against H5N1 epitopes. The HI
and NT antibodies and the T cell response of the control animals
at all time points before challenge are the same as the pretested
values.
Protective efficacy of AH/AAca in monkeys against
homologous and heterologous H5N1 virus challenge
Three weeks after the second vaccination, animals in each
group were challenged with an intratracheal inoculation of 10
6
EID50 of AH/05 virus (n=4) or BHG/05 virus (n=4) in a 3-ml
volume. Three days later, two animals from each group were
euthanized, and different parts of the respiratory system were
collected for virus titration and histologic and immunohistochem-
ical studies. The remaining animals were observed and euthanized
on day 15 postchallenge.
The control animals showed disease symptoms after challenge.
All eight control animals became anorexic on day 1 postchallenge,
and completely lost their appetites for two days. Four were
euthanized on day 3 postchallenge, while the remaining four
Figure 1. Vaccine efficacy of the AH/AAca virus in mice. (A) HI and (B) NT antibody responses to homologous (AH/05) and heterologous (BHG/
05) viruses after intranasal vaccination with 10
6 EID50 of AH/AAca in a 50-ml volume. Serum samples were collected on day 0 prevaccination (blue), 4
weeks after the first (orange) and 4 weeks after the second vaccination (pink). Asterisks indicate a statistically significant difference from antibody
titers measured at the preceding time point: **, P,0.01, *, P,0.05. (C–H) Protective efficacy against challenge with the AH/05 (C–E) or BHG/05 virus
(F–H). Weight changes (D and G) and survival rates (E and H) are shown only for the groups that were immunized once. The data in panels A–C and F
are reported as means6s.d.; the dashed blue lines in these panels indicate the lower limit of detection. p.c., postchallenge.
doi:10.1371/journal.ppat.1000409.g001
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control animals challenged with AH/05 and three challenged with
BHG/05 developed fever within the first 2 days postchallenge
(Figure 4A and 4B). By contrast, the vaccinated animals remained
healthy during the 15 days of observation post-challenge with
either the AH/05 or BHG/05 virus. The appetites and body
temperatures of the vaccinated animals were unchanged during
this period (Figure 4A and 4B).
In the vaccinated animals, the HI and NT antibody titers
measured at 2 weeks postchallenge were approximately the same
as those recorded at 2 weeks after the second vaccination
(Figure 2B–2E). HA-specific T cell responses increased on week
1 after challenge, and the peak response was detected at 2 weeks
postchallenge (Figure 3). While in the control animals, although
the titers of antibodies measured by ELISA reached 400–800, the
HI and NT antibody, and the HA-specific T cell responses were
not detected at 2 weeks after challenge (data not shown).
Lung tissue from four vaccinated macaques euthanized on day 3
postchallenge with either BHG/05 or AH/05 lacked macroscopic
lesions, had only mild-to-moderate bronchopneumonia with
prominent peribronchiolar lymph follicles apparent on micro-
scopic observation, and were free of detectable viral antigen
(Figure 5A, 5B, 5E, 5F, and 5I). A spectrum of macroscopic
lesions—including congestion, exudation, and consolidation—
were observed in the lung lobes of two unvaccinated control
animals challenged with the BHG/05 virus (C3 and C4) and one
challenged with the AH/05 virus (C1). Only prominent swelling of
the lymph nodes and tonsil were seen in another control animal
(C2) challenged with the AH/05 virus. Moderate-to-severe
bronchopneumonia with prominent viral antigen expression was
a characteristic finding in the nonvaccinated animals (Figure 5C,
5D, 5G, 5H, and 5I; also Table 5).
Virus was not isolated from any of the organs tested in the four
vaccinated animals challenged with either the AH/05 or BHG/05
virus (Figure 6A and 6B), but was found at high titers in the
trachea, bronchus, lung, lymph nodes, and tonsil of the four
unvaccinated animals on day 3 postchallenge (Figure 6A and 6B).
Among the eight macaques euthanized on day 15 postchallenge,
virus was isolated from tonsil of the two control animals challenged
with AH/05 virus (C5 and C6) at titers of 5.3 and 5.7 log10EID50/
g, respectively (Figure 6C), but not from either of the two
vaccinated animals. Virus was recovered at a low titer from the
nasal swab of a single macaque (C8) on day 4 postchallenge and of
another (C6) on day 6 postchallenge (Figure 6D).
Figure 2. Antibody responses of nonhuman primates. (A) H5N1-
specific antibody levels assessed by ELISA. Hemagglutination-inhibition
(HI) antibody to AH/05 (B) and BHG/05 (C) with chicken erythrocytes,
and microneutralization (NT) antibody to the AH/05 (D) and BHG/05 (E)
viruses. The HI antibody titers with horse erythrocytes were 4- to 8-fold
higher than those with chicken erythrocytes (data not shown). Titers are
reported for individual vaccinated animals. Blue dashed lines indicate
the lower limit of detection. Wpd1/2, week postvaccination dose 1 or 2;
wpc, week postchallenge. The P values indicate the antibody titers with
a significant increase from the preceding time point. In the control
animals, the HI and NT antibodies at all time points are the same as the
pretested values, only the ELISA antibody titers, ranged 400–800, were
detected at two weeks postchallenge (data not shown).
doi:10.1371/journal.ppat.1000409.g002
Figure 3. T cell responses against HA antigens in rhesus
macaques and its relationship to the neutralizing antibody. T
cell responses in the PBMC samples were measured by overlapping
peptides and ex-vivo IFN-c ELISPOT assay. Data shown are the mean
numbers 6s.d. of spot-forming cells (SFC) per 10
6 PBMCs to HA peptide
pools in the vaccinated animals at different time points after
vaccination and challenge. Neutralizing antibody in the serum samples
was measured by the microneutralization method using AH/05 virus
isolate, data shown are mean titers 6s.d. The T cell response and the
neutralizing antibody were not detected in the control monkeys at all
time points tested (data not shown).
doi:10.1371/journal.ppat.1000409.g003
Live Vaccine for H5N1 Influenza
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We generated a reassortant H5N1 cold-adapted virus, AH/
AAca, using reverse genetics in Vero cells, and evaluated its
immunogenecity and efficacy as a live attenuated vaccine. The
virus retained both the ca and ts phenotypes of the AAca virus, and
was attenuated in chickens, mice and monkeys. After a single
immunizing dose, the vaccine induced strong HI and NT antibody
responses to H5 influenza virus in mice and protected them from
homologous and heterologous H5N1 virus challenges. Most
importantly, after two immunizations, the vaccine induced both
humoral and T cell immune response in nonhuman primates and
completely protected these animals from challenge with either
homologous or heterologous H5N1 virus. Our results warrant
human testing of the AH/AAca virus as a candidate live
attenuated pandemic vaccine for use against H5N1 influenza
virus.
The H5N1 viruses are divided into ten distinct phylogenetic
clades (0–9) based on their HA genes. Those associated with
human infection are all from either clade 1, representing viruses
isolated mainly from patients in Thailand and Vietnam, or clade 2,
in which the viruses have been further divided into different
subclades [23]. The clade 2.1 viruses are circulating only in
Indonesia, while the clade 2.2 and 2.3 viruses continue to infect
poultry and humans in multiple countries, posing severe threats to
public health [23]. The H5N1 pandemic vaccines evaluated to
date are all based on clade 1 [9–11,17] or calde 0 viruses [16,17],
and their efficacy against clade 2 viruses is quite limited [17]. The
AH/AAca vaccine we described provides complete protection
against challenge with viruses from both clades 2.2 and 2.3;
moreover, the monkey antisera induced by AH/AAca cross
reacted well with clade 1 virus as in an HI test (data not shown).
The H5N1 viruses, AH/05 and BHG/05, replicate in multiple
organs in mice after intranasal inoculation (Table 2), however, our
preliminary studies indicate that these viruses could not replicate
in monkeys after intranasal inoculation, but they replicate
Table 4. T cell peptides and their corresponding T cell subsets against H5 HA in monkeys vaccinated with AH/AAca.
HA peptide
a T cell response to the peptide
Peptide sequence
Amino acid
position SFC/million PBMC
b
No. animals
responding T cell subset
c
VKSDQICIGYHANNSTEQV 14–32 375 1/8 CD4+
MEKNVTVTHAQDILEKTH 45–53 500 1/8 CD4+
NPMCDEFINVPEWSYIV 79–96 200 1/8 CD4+
LCYPGNFNDYEELKHLL 105–121 250–332 2/8 CD4+
NDYEELKHLLSRINHFEK 111–129 267 1/8 CD8+
PKSSWSDHEASSGVSSA 134–150 186 1/8 CD8+
SFFRNVVWLIKKNNTY 158–173 349–476 2/8 CD4+
NDAAEQTKLYQNPTTYI 198–204 50–66 3/8 CD4+
KLYQNPTTYISVGTSTL 214–221 625 1/8 CD4+
VPKIATRSKVNGQSGRM 226–242 143–169 3/8 CD4+
ILKPNDAINFESNGNFIA 248–265 375 1/8 CD4+
GWQGMVDGWYGYHHSNEQ 358–375 175 1/8 CD4+
LKREEISGVKLESIGTY 513–529 188 1/8 CD4+
aSequences were based on the HA gene of A/Anhui/1/05 virus.
bThe numbers of IFN-c–positive T lymphocytes in PBMC samples expressed as spot-forming cells (SFC)/million PBMCs were determined by HA overlapping peptides and
IFN–ELISPOT assay.
cT cell subset of the HA-specific T cells in PBMC samples was further determined by cell depletion using magnetic beads against CD8 and IFN-c ELISPOT assay.
doi:10.1371/journal.ppat.1000409.t004
Figure 4. Body temperature of nonhuman primates after
challenge with AH/05 virus. Change in body temperature in
nonhuman primates after challenge with AH/05 virus (A) or BHG/05
virus (B). Changes were calculated by subtracting the mean temper-
ature 3 days before challenge from the temperature recorded on the
indicated day.
doi:10.1371/journal.ppat.1000409.g004
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upon intratracheal inoculation, as has been seen with human
patients [24]. This is why we challenged the monkeys with
intratracheal inoculation instead of the intranasal inoculation.
Despite introduction of the challenge virus into the trachea, a
preferred site of replication for H5N1 viruses, the intranasal
immunization of the AH/AAca vaccine provided complete
protection to animals, further demonstrating the efficacy of this
live vaccine.
In a previous study, Suguitan et al [17] found differences in the
immunogenicity of three H5N1 live attenuated viruses. The
vaccine that contains the HA and NA genes from a clade 1 virus
(A/VN/1203/2004) was poorly immunogenic in mice, and was
not able to prevent the replication of the challenge viruses in lungs
and turbinates of mice (even two doses of the vaccine were not able
to prevent the replication of the challenge virus in ferrets). That
vaccine was also poorly immunogenic in humans (personal
communication from Dr. Subbarao). We also generated different
H5N1 live attenuated viruses with the surface genes derived from
different viruses that had been isolated in China. We found that
these reassortants possessed diverse replicative abilities and
induced varied antibody responses in mice; only the AH/AAca
vaccine proved highly immunogenic in both mice and monkeys.
These results suggest that the immunogenicity of H5N1 live
attenuated vaccine largely depends on the HA and NA genes,
emphasizing the need for careful selection of donor viruses when
preparing vaccines for a likely H5N1 influenza pandemic.
Although the precise responses that must be induced to protect
against H5N1 infection in humans are unknown, animal studies
indicate a central role for the cellular immune response [12].
Thus, in the face of a pandemic, a vaccine that elicits cellular
immunity could be valuable in reducing the severity of disease and
mortality, if not in providing complete protection from infection
[25]. Moreover, a vaccine that induces a cellular immune response
Figure 5. Vaccine efficacy in nonhuman primates assessed on the basis of lung lesions. Eight macaques were euthanized on day 3
postchallenge with AH/05 virus (A–D) or BHG/05 virus (E–H). Vaccinated animals (A,B,E,F) had less extensive bronchopneumonia (i.e., smaller foci of
consolidation) than did unvaccinated animals (C,D,G,H). The vaccinated animals also showed prominent peribronchial lymph follicles (a, e; arrows),
and their consolidated lung areas lacked viral antigen-positive cells (B,F). By contrast, the unvaccinated animals had lung lesions of moderate size
with a wide consolidated area (C,G; outlined by yellow dashes), smaller and less abundant peribronchial lymph follicles (C,G; arrows), and pneumonic
lesions containing many antigen-positive cells (D,H; brown pigment). (I) Schematic diagrams indicating distribution of pathologic lesions in the lungs
of animals vaccinated and challenged with AH/05 (V1 and V2); nonvaccinated and challenged with AH/05 (C1 and C2); vaccinated and challenged
with BHG/05 (V3 and V4); and nonvaccinated and challenged with BHG/05 (C3 and C4). In vaccinated animals, scant-to-moderate bronchopneumonia
was present in each lobe, but viral antigens were not detected in the lesions (V1, V2, V3, and V4; purple). By contrast, more severe
bronchopneumonia was observed in nonvaccinated macaque lungs (C1, C2, C3, and C4). Moreover, viral antigens were prominent in the pneumonic
lesions in the most affected lung lobes (C1, C2, C3, and C4; red). One lung lobe was entirely affected by pneumonia after infection with the BHG/05
virus (C3). Purple, bronchopneumonia without viral antigen; red, bronchopneumonia with viral antigen.
doi:10.1371/journal.ppat.1000409.g005
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responses that may be effective against multiple virus strains. Ruat
et al [8] reported that inoculation of two doses of inactivated
vaccine (containing 30 mg of HA) with adjuvants in monkeys could
induce functional antibody and protect the animals from a
homologous H5N1 virus challenge, but that vaccine did not
induce any detecable cellular immune response. In the present
study, the HI antibody titers induced by two doses of the AH/
AAca vaccine in monkeys were higher than those achieved with
two doses of the inactivated vaccine in the study of Ruat et al [8].
Two doses of AH/AAca vaccine also induced strong T cell
responses, which may play an important role in the sterile
protection of monkeys after H5N1 influenza virus challenge.
Whether cold-adapted, live attenuated H5N1 vaccines would be
sufficiently immunogenic to merit their widespread use during a
pandemic remains unclear, the use of live influenza H5N1
vaccines before a pandemic would be difficult to justify, as this
strategy would introduce a new HA gene into human populations.
Nonetheless, considering the efficacy shown by our vaccine in
nonhuman primates, we suggest that it has strong potential as an
effective H5N1 virus countermeasure, warranting further evalu-
ation in humans.
Materials and Methods
Viruses
The H5N1 virus AH/05 was isolated from the tracheal
secretion of a patient with lethal outcome from Anhui province
in China in 2005 [26,27], the BHG/05 virus and the GS/GD/96
viruses were isolated from a bar-headed goose and a goose,
respectively, as described previously [1,28], and the CK/SX/06
virus was isolated from a chicken in northern China in 2006. Virus
stocks were propagated in specific-pathogen free chicken embryos
or MDCK cells. The PB2, PB1, PA, NP, M and NS genes of the
AAca virus were synthesized (Jinsite Biotechnology, www.jinsite.
com.cn) and inserted into the viral RNA-mRNA bidirectional
expression plasmid pBD as described previously [29]. The HA and
NA genes of the AH/05 virus were amplified by RT-PCR and
inserted into pBD; the region that encodes basic amino acids at the
HA cleavage site of the plasmid was modifed to encode the amino
acid sequence corresponding to the sequence in the avirulent virus
HA as described previously [16,22]. AH/AAca virus was
generated by reverse genetics [18,19,20]. Virus stock was
propagated in specific pathogen-free chicken eggs.
Phenotypic analysis of the ca reassortant viruses
The ca and ts phenotype and the replication of AH/AAca in
chickens were tested as previously described [30].
Detection of antibodies
Serum antibody against H5N1 influenza virus was detected by
IgG ELISA essentially as described by DiNapoli et al [31] using
400 ng of AH/AAca virus, which was grown in eggs and purified
by ultracentrifugation though a 30% sucrose cushion, to coat the
96-well Immulon 1B plates (Dynex Technologies, Inc., www.
dynextechnologies.com). The pretest ELISA values (range 20–80)
are the background; which have been subtracted from the
experimental values of the monkeys. Sera were treated with
Vibrio cholerae (Denka-Seiken, www.denka-seiken.co.jp) receptor-
destroying enzyme before being tested for the presence of HI
antibody with 0.5% (V/V) chicken erythrocytes. The antigens
used were homologous wild-type H5N1 virus or BHG/05 virus.
The NT antibody titers were tested in MDCK cells with heat-
inactivated sera collected from mice or animals. HI and NT
antibody titers were transformed into log10 titers for the
calculation of mean6s.d. values.
IFN-c ELISPOT assay
The frequencies of PBMC-derived T lymphocytes that released
IFN-c upon restimulation with H5 HA-derived peptide pools were
determined by an ELISPOT assay, using a Mabtech kit according
to the manufacturer’s instructions. Briefly, thawed PBMC samples,
isolated by Lymphoprep density gradient centrifugation (Axis-
Shield, www.axis-shield.com), were incubated without peptides at
37uCi n5 %C O 2 for 4 h. After washing, they were incubated for
20 h at a concentration of 20 mg/ml with peptides (18-mer
overlapped by 10 amino acids; Sigma, www.sigmaaldrich.com)
generated from a human H5N1 isolate (A/Anhui/01/05). PHA
mitogen was used as a positive control. Cells (200,000 per well)
were added to each well of the ELISPOT plates (Millipore, www.
millipore.com), which had been coated with antiprimate IFN-c
antibody (Mabtech clone G2.4), and incubated at 4uC overnight.
The wells were next washed six times with PBS to remove cells and
Table 5. Pathological lesions and antigen distribution in tissues of nonhuman primates infected with H5N1 viruses.
Challenge
virus Animal
Vaccination
with AH/AAca Tra Bro(R) Bro(L) Right lungs Left lungs Tonsil TBLN
Upper Middle Lower Upper Middle Lower
AH/05 V1 + 2/2
b 2/22 /2 +/22 /2 ++/2 +/22 /2 +/22 /22 /2
V2 + 2/22 /22 /2 +/2 +/2 +/2 +/22 /2 ++/22 /22 /2
C1 22 /22 /22 /2 ++/++ /++ + /++ +/2 +/2 ++/++ 2/22 /2
C2 22 /22 /22 /2 ++/+ 2/2 +/2 +/22 /2 ++/22 /22 /2
BHG/05 V3 + 2/22 /22 /2 +/22 /22 /2 +/22 /2 +/22 /22 /2
V4 + 2/22 /22 /2 +/2 +/2 +/22 /2 +/22 /22 /22 /2
C3 22 /22 /22 /2 +/++ + + /++ ++/++ +/2 +/2 +/+ 2/22 /2
C4 22 /22 /22 /2 ++/++ ++/++ ++/++ +/2 +/++ + /++ +/+ 2/2
Animals were vaccinated twice (4-week interval) with AH/AAca and challenged with AH/05 or BHG/05 virus. Tissues for pathological examination were collected 3 days
after viral challenge. Tra, trachea; Bro, Bronchus; TBLN, tracheobronchial lymph node.
bPathological lesions/viral antigens. 2, no pathological change/antigen. +, limited pathological change/antigen. ++, moderate pathological change/antigen. +++, severe
pathological change/abundant antigen.
doi:10.1371/journal.ppat.1000409.t005
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PLoS Pathogens | www.plospathogens.org 8 May 2009 | Volume 5 | Issue 5 | e1000409Figure 6. Viral replication in nonhuman primates. Virus titers were determined in embryonated eggs injected with tissue homogenates on day
3 (A,B) and day 15 (C) postchallenge with AH/05 virus or BHG/05 virus. Virus was not detected in tissues harvested day 15 postchallenge from animals
challenged with the BHG/05 virus (data not shown). Titers are reported for tissues from individual animals, as log10 EID50/g tissue. The dashed blue
lines indicate the lower limit of detection. (D) Nasal swabs were collected from all living animals on days 2, 4, and 6 postchallenge for virus isolationi n
eggs.
doi:10.1371/journal.ppat.1000409.g006
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monoclonal antibody (Mabtech clone 7-B6-1) in PBS containing
0.5% BSA for 2 h at room temperature. After another three
washes with PBS, an avidin-alkaline phosphatase complex was
added, followed by incubation for 1 h at room temperature. The
wells were then washed, incubated with BCIP substrate (BioRad,
www.bio-rad.com) for 15 min at room temperature, rinsed with
distilled water to halt spot development, dried and read with an
automated ELISPOT reader (AID, www.elispot.com). The
number of spot-forming cells (SFCs) from each well was
determined for each animal after subtraction of counts from cells
cultured without peptide. A response was considered positive if
SFCs exceeded 20 per 10
6 PBMCs. The average response for
negative peptides and mock controls was 3 SFC/million PBMC.
The H5 HA response of each animal was taken the sum of the
IFN-c positive responses from all HA pools after subtraction of
background counts.
To confirm the presence of peptide induced IFN- c responses
and their relationship to CD4+ or CD8+ T lymphocytes, we tested
individual peptides from the first ELISPOT using a two-
dimensional matrix system in a second ELISPOT assay, using
thawed PBMC samples depleted of CD8+ T lymphocytes. Cell
depletion was carried out with nonhuman primate CD8+-specific
microbeads according to the manufacturer’s instructions (Miltenyi
Biotec, www.miltenyibiotec.com). CD8+ lymphocytes in the
PBMC samples were removed by labeling the cells with specific
microbeads in buffer containing PBS pH7.2, 0.5% BSA and
2 mM EDTA and then applying a magnetic field. Undepleted
PBMCs were used as positive controls.
Mouse study
Six-week-old female specific-pathogen-free BALB/c mice were
used in this study. The wild-type and reassortant viruses were both
tested for their replicative capacity, and the dose required to kill
50% of the mice (MLD50) was determined as described previously
[1]. For the immunogenicity study, groups of 5 mice were
anesthetized with CO2 before they were inoculated intranasally
once or twice (4 weeks apart) with 10
6 EID50 of the GSGD/AAca,
CKSX/AAca or AH/AAca virus. Sera were collected at 4 weeks
after the first vaccination or second vaccination for the HI and NT
antibody detection using the homologous wild-type H5N1 virus as
antigen. For the vaccine study, 80 6-week-old female specific-
pathogen-free BALB/c mice were anesthetized with CO2 before
they were inoculated intranasally once or twice (4 weeks apart)
with 10
6 EID50 of the AH/AAca in a 50 ml volume or with PBS as
control. Serum samples were collected from six mice in each group
at 4 weeks after the first and second immunizations and were
examined for HI and NT antibody using the homologous AH/05
virus and heterologous BHG/05 virus as antigens. Four weeks
after vaccination, the mice were challenged with 100 MLD50 of
the AH/05 (10
3.5EID50) or BHG/05 (10
3.6EID50) virus intrana-
sally; three mice from each group were killed on day 3
postchallenge, and their organs collected for virus titration. The
remaining seven mice were observed for 15 days for body weight
change and death.
Macaque study
Sixteen female rhesus macaques (Macaca mulatta) 2 or 3 years of
age were divided into two groups of eight animals each; one group
(V1–V8) was inoculated intranasally twice (4 weeks apart) with 10
7
EID50 of the AH/AAca virus in a 1-ml volume, while the other
(C1–C8) received the same volume of PBS as a control. Serum
samples were collected from each animal at 2 and 4 weeks after the
first immunization and 2 weeks after the second immunization.
Three weeks after the second immunization, the animals in each
group were challenged by intratracheal inoculation of 10
6 EID50
of AH/05 virus (n=4) or BHG/05 (n=4) virus in a 3 ml volume.
Three days later, two animals from each subgroup were
euthanized, and different parts of their respiratory system were
collected for virus titration and histologic and immunohistochem-
ical examinations; the remaining animals were observed and
euthanized on day 15 postchallenge. Nasal swabs were collected
from all of the animals on days 2, 4 and 6 postchallenge for virus
isolation in eggs.
Pathologic examination
Tissues fixed in 10% phosphate-buffered formalin were
dehydrated, embedded in paraffin, cut into 5-mm thick sections,
and stained with standard hematoxylin-and-eosin. Immunohisto-
chemistry was performed with antibodies to an H5 virus (A/
Vietnam/1203/04) using the Dako Envision system (Dako, www.
dako.com).
Animal facility
Studies with highly pathogenic H5N1 avian influenza viruses
inoculated into mice and macaques were conducted in a
biosecurity level 3+ laboratory approved by the Chinese Ministry
of Agriculture. All animal studies were approved by the Review
Board of Harbin Veterinary Research Institute, Chinese Academy
of Agricultural Sciences.
Statistical analysis
Virus titers in mice, antibody titers of mice and monkeys were
compared with a two-sided t-test.
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